Julie DeSander

Julie serves as the VP of Business Development and Alliance Management. At Agenus, Julie led the closure of $1.8B transaction with Gilead, $210M transaction with UroGen, $135M transaction with Betta Pharmaceuticals, as well as multiple research collaborations, including partnerships with Amgen and UCB. She also oversees Agenus’ strategic alliances, including Gilead, Incyte, Betta, UroGen, Merck and GSK. Prior to Agenus, Julie has more than 10 years of cross-functional experience in the biopharmaceutical industry with leadership roles in business development, corporate strategy, finance, and program management at Baxalta, Amgen, Siamab Therapeutics, McKinsey & Company and the Frankel Group. Julie holds a Master’s of Business Administration from MIT Sloan and a Master’s degree in Biomedical Enterprise from the Harvard/MIT Division of Health Sciences and Technology.